Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
Go back to Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy| (NASDAQ: TNYA) | Delayed: 0.68 +0.01 (1.49%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.67 | 52 Week High | $ | |||
| Open | $0.68 | 52 Week Low | $ | |||
| Day High | $0.71 | P/E | N/A | |||
| Day Low | $0.67 | EPS | $ | |||
| Volume | 4,856,684 | |||||
